v3.26.1
Equity-Accounted Investees and Joint Business - Most recent financial statements available of the main equity-accounted investments of Grifols (Details) - EUR (€)
€ in Millions
12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
[1]
Equity-Accounted Investees and Joint Business        
Non-current assets € 14,638 € 15,677    
Cash and cash equivalents 825 980 € 529 [1] € 549
Non-current financial liabilities (9,091) (9,491)    
Current financial liabilities (552) (676)    
Net revenue 7,524 7,212 6,592 [1]  
Consolidated net profit 500 213 163 [1]  
Grifols Egypt for Plasma Derivatives S.A.E.        
Equity-Accounted Investees and Joint Business        
Non-current assets 115 98    
Current assets 101 92    
Cash and cash equivalents 22 29    
Non-current liabilities (9) (7)    
Non-current financial liabilities (8) (7)    
Current liabilities (46) (45)    
Net assets 175 160    
Net revenue 28 13    
Consolidated net profit (13) € 4 (4)  
Shanghai RAAS Blood Products Co., Ltd.        
Equity-Accounted Investees and Joint Business        
Net revenue     778  
Consolidated net profit     € 234  
Grifols Canada Plasma, Inc.        
Equity-Accounted Investees and Joint Business        
Non-current assets 13      
Current assets 8      
Cash and cash equivalents 2      
Non-current liabilities (7)      
Non-current financial liabilities (7)      
Current liabilities (18)      
Net assets (9)      
Net revenue € 3      
[1] (See Note 2.d)